Cross Country Healthcare Announces Challenging 2025 Results, Strategic Initiatives, and Outlook for 2026

Boca Raton, Fla., March 4, 2026 – Cross Country Healthcare, Inc. (Nasdaq: CCRN) has released its fourth quarter and full year 2025 financial results, accompanied by significant business developments and strategic actions that may impact shareholder value. Below is an in-depth analysis of the report, highlighting key financial metrics, major corporate actions, and forward-looking statements that investors should closely monitor.

Key Financial Highlights for Q4 and Full Year 2025

• Revenue: Q4 2025 revenue was \$236.8 million, down 24% year-over-year and 5% sequentially. Full year 2025 revenue totaled \$1.05 billion, a decrease of 22% compared to 2024.
• Profitability: Consolidated gross profit margin for Q4 was 20.3%, up 30 basis points YoY but down 10 basis points sequentially. Full year gross margin was 20.3%, down 10 basis points from 2024.
• Net Loss: Q4 net loss attributable to common stockholders was \$82.9 million (compared to \$3.8 million in Q4 2024), largely due to a \$77.9 million goodwill and trade name impairment charge and a \$29.6 million valuation allowance against deferred tax assets. Full year net loss was \$94.9 million, a significant increase from \$14.6 million in 2024.
• Diluted EPS: Q4 diluted EPS was a loss of \$2.56 (versus a loss of \$0.12 in Q4 2024). Full year diluted EPS was a loss of \$2.93.
• Adjusted EBITDA: Q4 Adjusted EBITDA was \$4.1 million (1.7% margin), down from \$9.3 million (3.0% margin) in Q4 2024. Full year Adjusted EBITDA was \$26.8 million (2.5% margin), a 45% decrease from 2024.
• Adjusted EPS: Q4 Adjusted EPS was \$(0.06), compared to \$0.04 in Q4 2024. Full year Adjusted EPS was \$0.02, compared to \$0.46 in 2024.
• Cash Flow: Net cash provided by operating activities for Q4 was \$18.2 million (down 25% YoY). Full year operating cash flow was \$48.3 million, a 60% decline from 2024.

Business Segment Performance

Nurse and Allied Staffing

• Revenue was \$194.2 million in Q4, down 24% YoY and 4% sequentially.
• Contribution income fell to \$12.6 million from \$20.3 million in Q4 2024.
• Average field contract personnel (FTE) was 6,318, down from 7,621 in Q4 2024.
• Revenue per FTE per day was \$333, compared to \$363 in Q4 2024.

Physician Staffing

• Revenue was \$42.5 million in Q4, down 20% YoY and 12% sequentially.
• Contribution income was \$3.3 million, slightly down YoY.
• Total days filled were 18,599, down from 25,427 in Q4 2024.
• Revenue per day filled increased to \$2,286 (from \$2,085 in Q4 2024).

Strategic Actions and Shareholder-Sensitive Events

• Termination of Aya Merger Agreement: The fourth quarter was marked by the termination of the Aya Merger Agreement, triggering a decline in the company’s equity market capitalization, a \$77.9 million goodwill impairment charge, and receipt of a \$20 million termination fee. The company recorded this fee as operating cash flow, providing a temporary boost to liquidity.
• Share Buyback: During Q4, Cross Country repurchased over 800,000 shares (2.5% of shares outstanding) for a total of \$6.5 million, at an average price of \$8.10 per share. \$34 million remains available for further repurchases.
• Headcount Reduction: US headcount was reduced by 21% in 2025, yielding cost savings through the company’s India center of excellence.
• Strong Balance Sheet: As of December 31, 2025, Cross Country had \$109 million cash and no debt. Borrowing base under its asset-based credit facility was \$114.6 million, with \$96.3 million available net of letters of credit.
• Leadership Changes: Severance costs for executive transition in Q4 2025 were \$6.0 million, stemming from the former CEO’s separation.
• Technology Investment: The company continues to invest in its proprietary Intellify® platform, which processed 5.7 million hours in 2025 and is now live with 95% of MSP and vendor-neutral clients.

Forward-Looking Guidance and Outlook

• Q1 2026 Guidance:
  • Revenue: \$235–\$240 million (down 20–18% YoY, flat to slightly up sequentially)
  • Adjusted EBITDA: \$4–\$5 million (down 54–42% YoY, up 2–23% sequentially)
  • Adjusted EPS: \$(0.06)–\$(0.04)
• Management Commentary: CEO Kevin C. Clark expressed optimism for 2026, noting improved market signals and the potential for sequential growth, targeting a year-end revenue run-rate north of \$1 billion and profit margins between 4–5%.

Additional Shareholder Considerations

• Major Impairment Charges: The \$77.9 million impairment charge and \$29.4 million deferred tax asset valuation allowance are non-recurring but materially affected 2025 results.
• Risk Disclosure: The company cited multiple risks in its forward-looking statements, including market, regulatory, leadership, and operational uncertainties.
• Cash Flow and Liquidity: Despite a significant reduction in cash flow from operations, Cross Country maintains a strong cash position and no debt, providing flexibility for future initiatives or share repurchases.
• Conference Call: Investors are invited to participate in the company’s conference call on March 4, 2026, for further discussion and Q&A.

Financial Summary Tables

• Balance Sheet: As of December 31, 2025: \$449 million in total assets, \$126 million in total liabilities, \$323 million in equity.
• Cash Flow: Q4 net operating cash flow was \$18.2 million; full year \$48.3 million.
• Segment Data: Nurse and Allied Staffing accounted for 82% of revenue in Q4, Physician Staffing 18%.

Potential Price-Sensitive Information

• Termination of Aya Merger Agreement – triggered substantial goodwill impairment and caused a drop in share value; however, the receipt of a \$20 million termination fee provided a temporary liquidity boost.
• Significant Net Losses and Impairments – these may weigh on investor sentiment and share price in the short term.
• Share Repurchase Program – buybacks may support share price and indicate management’s confidence.
• Cost Savings and Technology Investments – may improve profitability in future periods.
• Leadership Changes – executive transition may affect operational and strategic direction.
• 2026 Outlook – management’s guidance for sequential improvement, increased margins, and focus on proprietary technology may be positive for long-term holders.

Conclusion

Cross Country Healthcare’s 2025 financial report reveals a year of significant challenges, strategic pivots, and forward-looking optimism. Investors should pay close attention to the impact of the Aya merger termination, large impairment charges, share buyback activity, cost-saving measures, and management’s outlook for improving margins and technology-driven growth in 2026. The company’s strong liquidity and absence of debt provide a foundation for resilience, but risks associated with market conditions, leadership changes, and operational transitions remain.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks, uncertainties, and changes in circumstances. Investors should consult the company’s SEC filings and confer with financial advisors prior to making investment decisions. The author assumes no responsibility for any investment actions taken based on this article.

View CROSS COUNTRY HEALTHCARE INC Historical chart here